tag:blogger.com,1999:blog-6235733697979948062.post760267263067424313..comments2024-03-19T00:33:30.191-07:00Comments on our brain tumor cocktails and stories: Updated statistics from Duke's modified poliovirus trial for recurrent GBMStephen Whttp://www.blogger.com/profile/00777652648990108253noreply@blogger.comBlogger5125tag:blogger.com,1999:blog-6235733697979948062.post-40354105519414652292017-07-09T08:43:03.998-07:002017-07-09T08:43:03.998-07:00Very encouraging. This is why I've flagged the...Very encouraging. This is why I've flagged the three trials at Duke and the one at Florida as being among my favorite clinical trials.<br /><br />https://clinicaltrials.gov/ct2/show/NCT02864368<br /><br />https://www.clinicaltrials.gov/ct2/show/NCT02366728<br /><br />https://www.clinicaltrials.gov/ct2/show/NCT02529072<br /><br />https://clinicaltrials.gov/ct2/show/NCT02465268<br /><br />Stephen Whttps://www.blogger.com/profile/00777652648990108253noreply@blogger.comtag:blogger.com,1999:blog-6235733697979948062.post-59249627150159980532017-07-09T08:37:42.759-07:002017-07-09T08:37:42.759-07:00It's hard to say from this abstract whether th...It's hard to say from this abstract whether the results are positive. They tell us there are 14 still alive and 6 remaining on study, but no mention of how long these patients have been followed up.<br /><br />Looks like it worked well in at least that one patient.Stephen Whttps://www.blogger.com/profile/00777652648990108253noreply@blogger.comtag:blogger.com,1999:blog-6235733697979948062.post-52526809823188250002017-07-09T07:53:17.746-07:002017-07-09T07:53:17.746-07:00DC PP65
Long-term Survival in Glioblastoma with ...DC PP65 <br /><br />Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination.<br /><br />Summary - DC PP65 injections (at least 3) paired with dose intensified TMZ (100 mg/m(2)/d × 21 days per cycle). Of the 11 persons in the trial - results: Median PFS and OS were 25.3 months and 41.1 months, exceeding survival using recursive partitioning analysis and matched historical controls. Four patients remained progression-free at 59 to 64 months from diagnosis.<br /><br />https://www.ncbi.nlm.nih.gov/m/pubmed/28411277/?Anonymoushttps://www.blogger.com/profile/18356538423121918160noreply@blogger.comtag:blogger.com,1999:blog-6235733697979948062.post-76456487761785357632017-07-09T07:30:07.810-07:002017-07-09T07:30:07.810-07:00Found the update on D2C7. Also looks positive.
...Found the update on D2C7. Also looks positive. <br /><br />Results: Currently, 23 subjects have been treated (16 male, 7 female) with a median age of 54 years. Out of 9 dose levels, 2 subjects have been treated at every dose except for 4 at dose level 3 (120 ng/ml) and 5 at dose 6 (405ng/ml).<br /><br />14 subjects are still alive with 6 remaining on study. So far, the longest survival time from infusion is 18.2+ months. Conclusions: D2C7-IT infusion via CED is safe with encouraging results. This dose escalation Phase I study is ongoing and will set the stage for the Phase II trial. <br /><br />Clinical trial information: NCT02303678<br /><br />http://abstracts.asco.org/199/AbstView_199_192413.htmlAnonymoushttps://www.blogger.com/profile/18356538423121918160noreply@blogger.comtag:blogger.com,1999:blog-6235733697979948062.post-38791618736073389802017-07-09T07:24:27.629-07:002017-07-09T07:24:27.629-07:00Thank you for posting Stephen. These statistics ar...Thank you for posting Stephen. These statistics are promising. I will be very interested to see the stats for DC PP66 and D2C7. Anonymoushttps://www.blogger.com/profile/18356538423121918160noreply@blogger.com